

# **Fibromyalgia Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by region, and Competition**

<https://marketpublishers.com/r/FF9F589AAD79EN.html>

Date: November 2023

Pages: 183

Price: US\$ 4,500.00 (Single User License)

ID: FF9F589AAD79EN

## **Abstracts**

Global Fibromyalgia Treatment Market has valued at USD 2.98 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 3.90% through 2028. Fibromyalgia treatment is a comprehensive approach aimed at managing the symptoms and improving the quality of life for individuals living with fibromyalgia, a chronic pain condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and often, psychological symptoms. Treatment for fibromyalgia typically involves a combination of medical, psychological, and lifestyle strategies tailored to the individual patient's needs and preferences. Physical therapists develop tailored exercise programs that focus on improving flexibility, strength, and overall physical function. Gentle, low-impact exercises are typically recommended, such as swimming, walking, or tai chi. Regular follow-up with healthcare providers is crucial to assess treatment effectiveness and make necessary adjustments to medications or other therapies. Monitoring for potential side effects and addressing them promptly is part of medication management.

The increasing prevalence of fibromyalgia worldwide, particularly in developed countries, has been a significant driver for the market. More people being diagnosed with fibromyalgia creates a larger patient pool in need of treatment. Ongoing research into the underlying causes of fibromyalgia and the development of new treatment

modalities have expanded the range of available therapies and driven market growth. Pharmaceutical companies have been actively investing in the development of drugs specifically targeting fibromyalgia symptoms, including pain, sleep disturbances, and mood disorders. The trend toward multimodal approaches to fibromyalgia treatment, combining medications, physical therapy, psychological interventions, and lifestyle changes, has increased the demand for various treatment options. Government healthcare initiatives and policies aimed at improving the management of chronic pain conditions, including fibromyalgia, have bolstered the market. As the global population continues to age, the prevalence of chronic pain conditions like fibromyalgia is expected to rise, further boosting the demand for treatment. A shift toward patient-centric care, where treatment plans are tailored to individual needs and preferences, has increased the demand for a variety of treatment options.

## Key Market Drivers

### Advancements in Research

One of the significant challenges in fibromyalgia has been the lack of objective diagnostic biomarkers. Researchers have been working to identify biomarkers in blood, cerebrospinal fluid, or other biological samples that could aid in the diagnosis and monitoring of fibromyalgia. Genetic research has provided insights into the genetic predisposition to fibromyalgia. Identifying specific genetic markers associated with the condition may lead to targeted treatments in the future. Research has emphasized the role of central sensitization, which involves an amplified response to pain signals in the central nervous system. Understanding these mechanisms has led to the development of medications targeting neurotransmitters involved in pain perception. Some studies have suggested that neuroinflammation may play a role in fibromyalgia. Investigating the involvement of inflammatory processes in the central nervous system has led to potential treatment approaches. Advancements in neuroimaging techniques, such as functional MRI (fMRI) and positron emission tomography (PET), have allowed researchers to visualize and study brain activity in individuals with fibromyalgia. These studies help in understanding how pain processing differs in fibromyalgia patients. Pharmaceutical companies have been conducting clinical trials for medications targeting fibromyalgia symptoms, including pain, sleep disturbances, and mood disorders. Some medications, such as duloxetine and pregabalin, have received regulatory approvals for fibromyalgia treatment.

Research has supported the effectiveness of non-pharmacological treatments, including cognitive-behavioral therapy (CBT), exercise therapy, and mindfulness-based

interventions, in improving fibromyalgia symptoms and quality of life. There is a growing emphasis on personalized medicine in fibromyalgia treatment, where treatment plans are tailored to individual patient profiles based on factors like symptom severity, comorbid conditions, and genetic markers. Researchers are increasingly incorporating patient-reported outcomes and quality of life assessments in clinical trials to better understand treatment efficacy from the patient's perspective. The use of digital health tools and wearables has allowed for real-time monitoring of fibromyalgia symptoms and treatment responses, providing valuable data for research and patient care. Research has explored the effectiveness of complementary and alternative therapies, such as acupuncture, yoga, and dietary interventions, as adjuncts to traditional treatment approaches. Long-term observational studies are helping researchers gain insights into the natural progression of fibromyalgia, treatment outcomes over time, and factors that influence symptom fluctuations. This factor will help in the development of the Global Fibromyalgia Treatment Market.

### High Prevalence of Fibromyalgia

Fibromyalgia affects a substantial number of individuals worldwide. The condition is estimated to impact millions of people, and its prevalence varies from region to region. A larger patient population naturally leads to a higher demand for treatment options. As awareness about fibromyalgia has grown among healthcare professionals and the public, more individuals are seeking medical attention and diagnosis. This increased awareness results in more people being identified as having fibromyalgia and subsequently needing treatment. High prevalence often means that more healthcare providers are diagnosing fibromyalgia. Improved diagnostic criteria and guidelines also contribute to earlier and more accurate diagnoses, driving the need for appropriate treatment. Fibromyalgia can significantly impact a person's quality of life, causing pain, fatigue, sleep disturbances, and psychological symptoms. Individuals with fibromyalgia often seek treatment to improve their overall well-being and functional ability.

The economic burden of fibromyalgia, including healthcare costs and lost productivity, is substantial. As a result, individuals with fibromyalgia and healthcare systems have a strong incentive to find effective treatments to reduce the economic impact of the condition. The high prevalence of fibromyalgia has motivated pharmaceutical companies and researchers to invest in the development of new treatments. This investment in research and innovation contributes to the availability of a variety of treatment options. Patient advocacy groups and organizations have played a crucial role in raising awareness about fibromyalgia and advocating for better treatment options. They contribute to a greater demand for effective therapies. Fibromyalgia is

more common in middle-aged and older adults. As the global population continues to age, the prevalence of fibromyalgia is expected to rise, further increasing the demand for treatment. The recognition that fibromyalgia often requires a combination of treatment approaches, including medications, physical therapy, and psychological interventions, drives the demand for a comprehensive and personalized treatment plan. This factor will pace up the demand of the Global Fibromyalgia Treatment Market.

### Increasing Pharmaceutical Innovations

Pharmaceutical companies are continually researching and developing new medications specifically designed to address the symptoms and underlying mechanisms of fibromyalgia. These innovative drugs aim to provide more effective and targeted treatment options for patients, increasing the demand for advanced therapies. Innovations in drug development lead to medications that are often more effective in managing the pain, sleep disturbances, and psychological symptoms associated with fibromyalgia. As the efficacy of treatments improves, more patients and healthcare providers seek these options. Pharmaceutical innovations may result in medications with fewer side effects or better tolerability profiles. Patients are more likely to adhere to treatment plans when they experience fewer adverse effects, which drives demand. When new fibromyalgia medications receive regulatory approvals, such as FDA approval in the United States or approvals from other relevant agencies worldwide, it legitimizes their use and encourages healthcare providers to prescribe them. This approval process is often based on clinical trials that demonstrate safety and efficacy. As patients become aware of new treatment options through healthcare providers, patient advocacy groups, and direct-to-consumer advertising, they may request these innovative treatments, driving demand within the market.

The presence of multiple pharmaceutical companies developing fibromyalgia treatments fosters competition. This competition can lead to a wider range of treatment choices and improved access for patients, ultimately increasing demand. Ongoing research into the underlying mechanisms of fibromyalgia and potential drug targets keeps the field dynamic. New discoveries may lead to the development of novel medications, which generate interest among healthcare providers and patients alike. Innovations may lead to more personalized and tailored treatment approaches. Tailoring treatments to individual patient need and profiles can result in better outcomes, driving demand for these specialized therapies. Innovations may also promote the use of combination therapies, where different drugs are used in tandem to address various fibromyalgia symptoms. This approach offers comprehensive symptom management and encourages the demand for multiple medications. As innovative fibromyalgia treatments

become available, their distribution often expands globally. This broader availability increases the global demand for advanced fibromyalgia therapies. This factor will accelerate the demand of the Global Fibromyalgia Treatment Market.

## Key Market Challenges

### Variability in Symptoms

Fibromyalgia is known for its heterogeneity, with patients experiencing a wide range of symptoms and symptom severity. What works for one patient may not work for another, leading to a need for personalized treatment plans tailored to everyone's unique symptoms and needs. The variability in symptoms can complicate the diagnostic process, as fibromyalgia can mimic other conditions. Healthcare providers must carefully consider the patient's symptom profile and medical history for accurate diagnosis. The response to treatments can vary significantly among patients. What may be effective in managing pain for one person might not have the same effect on another. This variability requires ongoing monitoring and adjustment of treatment plans.

Due to the diverse symptomatology, fibromyalgia often requires a multimodal treatment approach, combining medications, physical therapy, psychological interventions, and lifestyle modifications. Coordinating these various treatment modalities can be challenging. Finding the most effective treatment for a particular patient may involve a trial-and-error process, which can be frustrating for both patients and healthcare providers. This can also lead to delayed symptom relief. While some individuals primarily experience physical symptoms, others may have a significant psychological component to their fibromyalgia. This variability necessitates a holistic approach that addresses mental health alongside physical symptoms. Variability in treatment responses can impact patient satisfaction. Patients who do not experience relief from their symptoms may become disillusioned with treatment options. Conducting clinical trials and research on fibromyalgia treatments can be complicated by the diversity of symptoms. Researchers must carefully select and stratify study participants to ensure meaningful results. Developing standardized treatment guidelines can be challenging due to the variability in symptoms. Healthcare organizations and professional societies must consider this variability when creating recommendations.

### Limited Treatment Options

Fibromyalgia is a complex condition with a range of symptoms, including chronic pain, fatigue, sleep disturbances, and psychological symptoms. The limited treatment options



may not fully address all these symptoms for all patients, leading to incomplete symptom management. Some patients may not tolerate or respond well to the available medications commonly prescribed for fibromyalgia, such as antidepressants and anticonvulsants. This can limit treatment choices and effectiveness. Medications used to treat fibromyalgia can have side effects, which can be a barrier to their use. Patients may discontinue treatment due to intolerable side effects, leaving them with even fewer options. A subset of fibromyalgia patients may be resistant to the available treatments, meaning that these treatments have limited effectiveness. Identifying alternative treatments for these individuals can be challenging.

Some treatments, such as opioids, are not recommended for fibromyalgia due to concerns about dependence and addiction. The limited availability of effective non-opioid pain management options can be a challenge. Non-pharmacological treatments, including physical therapy, cognitive-behavioral therapy (CBT), and exercise, are important components of fibromyalgia management. However, access to and availability of these therapies can be limited, especially in some regions. Some fibromyalgia treatments, especially when considering a multimodal approach, can be costly. This can be a barrier for patients who may not have adequate insurance coverage or financial resources. There has been a need for the development of novel therapies specifically targeting fibromyalgia. The limited number of new drugs or treatments entering the market can hinder progress in improving treatment options. Limited treatment options can lead to patient dissatisfaction and frustration, as individuals may struggle to find a treatment that effectively manages their symptoms and improves their quality of life.

## Key Market Trends

### Lifestyle Management

Healthcare providers are increasingly adopting a multidisciplinary approach to fibromyalgia treatment, which includes lifestyle management as a core component. This approach may involve collaboration between rheumatologists, pain specialists, physical therapists, psychologists, and other healthcare professionals. Tailoring treatment plans to the individual patient's needs and preferences is a key aspect of managing fibromyalgia. Lifestyle management strategies are chosen based on the patient's specific symptoms, challenges, and goals. Regular exercise and physical activity have been shown to improve symptoms of fibromyalgia, including pain, fatigue, and sleep disturbances. Healthcare providers are increasingly recommending exercise programs tailored to the patient's capabilities and preferences. Some individuals with fibromyalgia find that dietary changes, such as reducing the consumption of certain foods or

additives, can help manage their symptoms. Nutrition counseling may be part of the treatment plan. Addressing sleep disturbances is a crucial aspect of fibromyalgia management. Lifestyle management includes adopting good sleep hygiene practices and developing a sleep routine that promotes restorative sleep. Stress can exacerbate fibromyalgia symptoms. Patients are often encouraged to practice stress-reduction techniques such as mindfulness, meditation, relaxation exercises, and stress management counseling.

Learning how to pace activities to avoid overexertion and symptom flares is a valuable lifestyle management skill for individuals with fibromyalgia. Occupational therapists may help patients develop effective pacing strategies. Cognitive-behavioral therapy (CBT) and other psychological interventions are used to address the psychological symptoms associated with fibromyalgia. Lifestyle management includes access to psychological support and coping strategies. For patients who are overweight or obese, weight management may be part of the treatment plan. Achieving and maintaining a healthy weight can help reduce the strain on joints and improve overall well-being. Healthcare providers emphasize patient education as a critical aspect of lifestyle management. Educating patients about their condition, self-care strategies, and the importance of adherence to treatment plans empowers them to take an active role in their health.

## Segmental Insights

### Drug class Insights

In 2022, the Global Fibromyalgia Treatment Market largest share was held by Antiepileptic segment and is predicted to continue expanding over the coming years. Antidepressant medications, particularly certain types of antidepressants like tricyclic antidepressants (TCAs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs), have been found to be effective in managing the chronic pain associated with fibromyalgia. These medications can help alleviate pain symptoms and improve the quality of life for fibromyalgia patients. Fibromyalgia is often characterized by neuropathic pain, which involves abnormalities in the way the nervous system processes pain signals. Antidepressants, especially SNRIs like duloxetine, are known to modulate neurotransmitters involved in pain perception, which can be beneficial for fibromyalgia patients. Antidepressants can also have a positive impact on sleep patterns, which are frequently disrupted in individuals with fibromyalgia. Improved sleep can contribute to better overall well-being and pain management. Fibromyalgia is often associated with symptoms such as depression and anxiety. Antidepressants, as the name suggests, are designed to address these mood-related symptoms, providing dual

benefits in managing both physical and emotional aspects of the condition.

### Distribution Channel Insights

In 2022, the Global Fibromyalgia Treatment Market largest share was held by Hospital Pharmacies segment and is predicted to continue expanding over the coming years. Hospital pharmacies often stock a wide range of specialized medications, including those used in the treatment of chronic and complex conditions like fibromyalgia. They are equipped to provide both inpatient and outpatient services, making them a convenient source for patients with fibromyalgia. Many patients with fibromyalgia are initially diagnosed and prescribed medications in hospital settings, particularly if they are admitted for pain management, diagnosis, or related health issues. Hospital pharmacies play a key role in dispensing these initial prescriptions. Fibromyalgia treatment may involve complex medication regimens, including the use of multiple medications to manage different symptoms. Hospital pharmacies are well-equipped to manage and dispense these complex regimens. Hospitals often have specialized pain clinics and rheumatology departments where patients with fibromyalgia receive comprehensive care. Hospital pharmacies are closely aligned with these departments, ensuring timely access to necessary medications. Fibromyalgia patients may occasionally require hospitalization for severe symptoms or complications. During hospital stays, medications are dispensed through hospital pharmacies.

### Regional Insights

The North America region dominates the Global Fibromyalgia Treatment Market in 2022. North America, particularly the United States, has reported a relatively high prevalence of fibromyalgia compared to other regions. This higher prevalence creates a larger patient population in need of treatment and drives demand for fibromyalgia-related healthcare services and products. North America boasts a well-developed and advanced healthcare infrastructure, with many specialized clinics, hospitals, and healthcare providers that focus on chronic pain management, including fibromyalgia treatment. The region is home to numerous pharmaceutical companies that invest in research and development of medications and therapies for fibromyalgia. These innovations are more readily available in the region. In North America, there is generally good access to healthcare services, which ensures that fibromyalgia patients can receive timely diagnoses and access to treatment options.

### Key Market Players



AbbVie Inc.

Teva Pharmaceutical Industries Ltd.

Amneal Pharmaceuticals LLC

Novartis AG

Zydus Lifesciences Limited

Viartis Inc.

Eli Lilly and Company

Sun Pharmaceutical Industries Limited

Abbott Laboratories Ltd.

Lupin Limited.

Report Scope:

In this report, the Global Fibromyalgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fibromyalgia Treatment Market, By Drug class:

Antidepressants

Antipileptic

Muscle Relaxants

Others

Fibromyalgia Treatment Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Fibromyalgia Treatment Market, By region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fibromyalgia Treatment Market.

Available Customizations:

Global Fibromyalgia Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL FIBROMYALGIA TREATMENT MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Drug Class (Antidepressants, Antipileptic, Muscle Relaxants, Others)
  - 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

- 5.2.3. By Region
- 5.2.4. By Company (2022)
- 5.3. Market Map

## **6. ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Drug Class
  - 6.2.2. By Distribution Channel
  - 6.2.3. By Country
- 6.3. Asia Pacific: Country Analysis
  - 6.3.1. China Fibromyalgia Treatment Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Drug Class
      - 6.3.1.2.2. By Distribution Channel
  - 6.3.2. India Fibromyalgia Treatment Market Outlook
    - 6.3.2.1. Market Size & Forecast
      - 6.3.2.1.1. By Value
    - 6.3.2.2. Market Share & Forecast
      - 6.3.2.2.1. By Drug Class
      - 6.3.2.2.2. By Distribution Channel
  - 6.3.3. Australia Fibromyalgia Treatment Market Outlook
    - 6.3.3.1. Market Size & Forecast
      - 6.3.3.1.1. By Value
    - 6.3.3.2. Market Share & Forecast
      - 6.3.3.2.1. By Drug Class
      - 6.3.3.2.2. By Distribution Channel
  - 6.3.4. Japan Fibromyalgia Treatment Market Outlook
    - 6.3.4.1. Market Size & Forecast
      - 6.3.4.1.1. By Value
    - 6.3.4.2. Market Share & Forecast
      - 6.3.4.2.1. By Drug Class
      - 6.3.4.2.2. By Distribution Channel
  - 6.3.5. South Korea Fibromyalgia Treatment Market Outlook
    - 6.3.5.1. Market Size & Forecast



- 6.3.5.1.1. By Value
- 6.3.5.2. Market Share & Forecast
  - 6.3.5.2.1. By Drug Class
  - 6.3.5.2.2. By Distribution Channel

## **7. EUROPE FIBROMYALGIA TREATMENT MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Drug Class
  - 7.2.2. By Distribution Channel
  - 7.2.3. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. France Fibromyalgia Treatment Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Drug Class
      - 7.3.1.2.2. By Distribution Channel
  - 7.3.2. Germany Fibromyalgia Treatment Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Drug Class
      - 7.3.2.2.2. By Distribution Channel
  - 7.3.3. Spain Fibromyalgia Treatment Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Drug Class
      - 7.3.3.2.2. By Distribution Channel
  - 7.3.4. Italy Fibromyalgia Treatment Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Drug Class
      - 7.3.4.2.2. By Distribution Channel
  - 7.3.5. United Kingdom Fibromyalgia Treatment Market Outlook

- 7.3.5.1. Market Size & Forecast
  - 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
  - 7.3.5.2.1. By Drug Class
  - 7.3.5.2.2. By Distribution Channel

## **8. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Drug Class
  - 8.2.2. By Distribution Channel
  - 8.2.3. By Country
- 8.3. North America: Country Analysis
  - 8.3.1. United States Fibromyalgia Treatment Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Drug Class
      - 8.3.1.2.2. By Distribution Channel
  - 8.3.2. Mexico Fibromyalgia Treatment Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Drug Class
      - 8.3.2.2.2. By Distribution Channel
  - 8.3.3. Canada Fibromyalgia Treatment Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Drug Class
      - 8.3.3.2.2. By Distribution Channel

## **9. SOUTH AMERICA FIBROMYALGIA TREATMENT MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast

- 9.2.1. By Drug Class
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
- 9.3. South America: Country Analysis
  - 9.3.1. Brazil Fibromyalgia Treatment Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Drug Class
      - 9.3.1.2.2. By Distribution Channel
  - 9.3.2. Argentina Fibromyalgia Treatment Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Drug Class
      - 9.3.2.2.2. By Distribution Channel
  - 9.3.3. Colombia Fibromyalgia Treatment Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value
    - 9.3.3.2. Market Share & Forecast
      - 9.3.3.2.1. By Drug Class
      - 9.3.3.2.2. By Distribution Channel

## **10. MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Drug Class
  - 10.2.2. By Distribution Channel
  - 10.2.3. By Country
- 10.3. MEA: Country Analysis
  - 10.3.1. South Africa Fibromyalgia Treatment Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Drug Class
      - 10.3.1.2.2. By Distribution Channel

### 10.3.2. Saudi Arabia Fibromyalgia Treatment Market Outlook

#### 10.3.2.1. Market Size & Forecast

##### 10.3.2.1.1. By Value

#### 10.3.2.2. Market Share & Forecast

##### 10.3.2.2.1. By Drug Class

##### 10.3.2.2.2. By Distribution Channel

### 10.3.3. UAE Fibromyalgia Treatment Market Outlook

#### 10.3.3.1. Market Size & Forecast

##### 10.3.3.1.1. By Value

#### 10.3.3.2. Market Share & Forecast

##### 10.3.3.2.1. By Drug Class

##### 10.3.3.2.2. By Distribution Channel

## 11. MARKET DYNAMICS

### 11.1. Drivers

### 11.2. Challenges

## 12. MARKET TRENDS & DEVELOPMENTS

### 12.1. Recent Developments

### 12.2. Product Launches

### 12.3. Mergers & Acquisitions

## 13. GLOBAL FIBROMYALGIA TREATMENT MARKET: SWOT ANALYSIS

## 14. PORTER'S FIVE FORCES ANALYSIS

### 14.1. Competition in the Industry

### 14.2. Potential of New Entrants

### 14.3. Power of Suppliers

### 14.4. Power of Customers

### 14.5. Threat of Substitute Product

## 15. PESTLE ANALYSIS

## 16. COMPETITIVE LANDSCAPE

## 16.1. AbbVie Inc.

- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis

## 16.2. Teva Pharmaceutical Industries Ltd.

- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis

## 16.3. Amneal Pharmaceuticals LLC

- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis

## 16.4. Novartis AG

- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis

## 16.5. Zydus Lifesciences Limited

- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis

## 16.6. Viatris Inc.

- 16.6.1. Business Overview
- 16.6.2. Company Snapshot



- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
- 16.7. Eli Lilly and Company
  - 16.7.1. Business Overview
  - 16.7.2. Company Snapshot
  - 16.7.3. Products & Services
  - 16.7.4. Financials (In case of listed companies)
  - 16.7.5. Recent Developments
  - 16.7.6. SWOT Analysis
- 16.8. Sun Pharmaceutical Industries Limited
  - 16.8.1. Business Overview
  - 16.8.2. Company Snapshot
  - 16.8.3. Products & Services
  - 16.8.4. Financials (In case of listed companies)
  - 16.8.5. Recent Developments
  - 16.8.6. SWOT Analysis
- 16.9. Abbott Laboratories Ltd.
  - 16.9.1. Business Overview
  - 16.9.2. Company Snapshot
  - 16.9.3. Products & Services
  - 16.9.4. Financials (In case of listed companies)
  - 16.9.5. Recent Developments
  - 16.9.6. SWOT Analysis
- 16.10. Lupin Limited.
  - 16.10.1. Business Overview
  - 16.10.2. Company Snapshot
  - 16.10.3. Products & Services
  - 16.10.4. Financials (In case of listed companies)
  - 16.10.5. Recent Developments
  - 16.10.6. SWOT Analysis

## **17. STRATEGIC RECOMMENDATIONS**

## **18. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Fibromyalgia Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by region, and Competition

Product link: <https://marketpublishers.com/r/FF9F589AAD79EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FF9F589AAD79EN.html>